ArticleMolecular biology reports2026
Circulating muscle- and inflammation-related microRNAs in breast cancer survivorship: associations with subtype, treatment, timing, and age.
Article in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeCancer and its treatments often lead to inflammation, muscle problems, and ongoing loss of physical function, as reflected by alterations in circulating microRNAs (miRNAs). In this study, we measured levels of selected muscle- (miR-1, miR-133, miR-208, miR-486, and miR-499) and inflammation-related (miR-21, miR-126, miR-146, and miR-155) miRNAs in breast cancer patients and aimed to explore, using stratified analyses, how their levels relate to cancer subtype, treatment modality, treatment timing, and age.
methodsWe collected 77 plasma samples from pretreatment and post-treatment breast cancer patients and healthy controls. Circulating miRNA levels were measured using quantitative reverse transcription polymerase chain reaction. We compared miRNA levels across different breast cancer subtypes, treatment modalities, treatment timing, and age groups.
resultsPretreatment patients with breast cancer did not show significant changes in the selected miRNAs compared with healthy controls. However, different breast cancer subtypes showed distinct patterns: Luminal A predominantly affected muscle-related miRNAs, and Luminal B affected inflammation-related miRNAs. Cancer treatment, especially surgery and chemotherapy, led to significant changes in miR-21 and miR-486, primarily within the first 91 days after cancer diagnosis. Increases in miR-133 and miR-486 after treatment were mostly seen in patients over 50 years old.
conclusionCirculating muscle- and inflammation-related miRNAs display distinct expression patterns associated with breast cancer subtype and treatment. Specifically, miR-21, miR-133, and miR-486 demonstrate sensitivity to cancer treatment exposure, timing, and patient age.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.